Applied Filters
EU backs compulsory licensing for COVID vaccines
The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.
Bardehle opens Paris life sciences practice with two hires
Munich-based firm Bardehle Pagenberg has established a life sciences practice at its Paris office with two recent hires.
UC Berkeley loses CRISPR patent at EPO
The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.
Sanofi and C4X in $493m licensing deal
UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Lundbeck loses €150m pay-for-delay appeal
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
UK implored to back COVID-19 IP waiver at WTO
The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.
Five minutes with… Penny Gilbert
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.
AstraZeneca to buy Alexion for $39bn
AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.
Danish university sues Creative Biolabs over ‘antibody pirating’
The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.
MSF urges EU to rid market of ‘avoidable suffering’ from SPCs
Médecins Sans Frontières has warned that the European Commission’s commitment to the supplementary protection certificate system risks undermining its promise to improve drug accessibility.
